At the IGTP TODAY

News

- Innovation

Nimble Diagnostics closes a financing round of one million euros

NIMBLE Diagnostics, a spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia – BarcelonaTech (UPC) and the University of Barcelona (UB), has successfully closed a funding round led by Grow Ventures together with Namarel Ventures and Inveniam Group where they have secured more than one million euros. NIMBLE is developing the first medical device to monitor patients with implanted stents, thus avoiding serious complications and improving the clinical management of millions of patients each year.

- Campus Can Ruti, Innovation

European Commission’s drive to launch a medical device created in the Hospital and the Germans Trias i Pujol Research Institute to improve the diagnosis and prognosis of the acute ischaemic stroke

The care and treatment provided to people who suffer an ischemic stroke can improve thanks to a technology developed in Catalonia. This is the purpose of Time is Brain (TiB), a start-up that arose from a scientific project carried out by the Hospital and the Germans Trias i Pujol Research Institute (IGTP), which has just received an investment by the European Union of almost 6 million euros in order for the hospitals to count on a pioneering device to manage acute ischaemic stroke.

- Innovation, Research

Biointaxis launches a 0.88M euro crowdfunding campaign to finance a curative therapy for Friedreich's Ataxia

Biointaxis is a spin-off of the IGTP led by Dr. Antoni Matilla-Dueñas. To date, the research has been financed with the support of patient associations, the founders themselves, La Caixa Foundation, the CDTI and the Ministry of Science and Innovation. The project, that received the European seal of excellence in 2020, is in the final phase of gene therapy after years of research progress and it is the only candidate with potential to cure the disease at the moment. This round aims to overcome  the critical inflexion point - the demonstration of the biodistribution and safety of the therapy in non-human primates. The value of the company will increase considerably when this data is available in less than 1 year; the financing campaign is being carried out through the equity crowdfunding platform of Capital Cell.